PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm

In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and  Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer. Topics include:

• Maintenance therapy in ovarian cancer
• SOLO1, PRIMA, PAOLO-1 clinical data
• Role of bevacizumab in treatment of ovarian cancer

Presenters:
Nicoletta Colombo, MD
Professor of Obstetrics and Gynecology
University of Milan-Bicocca
European Institute of Oncology
Milan, Italy

Philipp Harter, MD, PhD
Deputy Director
Department of Gynecology and Gynecologic Oncology
Evang. Kliniken Essen-Mitte
Essen, Germany

Alexandra Leary, MD, PhD
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Content based on an online CME program supported by an educational grant from AstraZeneca.

New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapy
https://bit.ly/3aF8Lui
 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.